Genomed SA (GEN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Sales of 25.05%, the company declared Very Positive results in Mar 25

OPERATING CASH FLOW(Y) Highest at PLN 2.12 MM
ROCE(HY) Highest at 21.32%
RAW MATERIAL COST(Y) Fallen by -195.5% (YoY)

With ROE of 21.50%, it has a fair valuation with a 3.74 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 37 Million (Micro Cap)

P/E

17.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.48

Return on Equity

28.05%

Price to Book

3.19

Revenue and Profits:

Net Sales:

6 Million

(Quarterly Results - Mar 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.72%

6 Months

7.69%

1 Year

10.24%

2 Years

-9.68%

3 Years

-18.13%

4 Years

-19.08%

5 Years

-19.08%

Genomed SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.86%

EBIT Growth (5y)

33.18%

EBIT to Interest (avg)

1.04

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

2.59

Tax Ratio

5.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

21.90%

ROE (avg)

8.65%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.74

EV to EBIT

13.71

EV to EBITDA

10.54

EV to Capital Employed

5.58

EV to Sales

1.36

PEG Ratio

0.07

Dividend Yield

ROCE (Latest)

40.69%

ROE (Latest)

21.50%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 26.00% vs -13.79% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 133.33% vs -500.00% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.30",
          "val2": "5.00",
          "chgp": "26.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "-0.40",
          "chgp": "225.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.20",
          "val2": "-0.60",
          "chgp": "133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "44.70%",
          "val2": "-101.00%",
          "chgp": "14.57%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.22% vs 9.76% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 22.22% vs 200.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23.00",
          "val2": "22.50",
          "chgp": "2.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.10",
          "val2": "2.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.10",
          "val2": "0.90",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "58.80%",
          "val2": "64.10%",
          "chgp": "-0.53%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

6.30

5.00

26.00%

Operating Profit (PBDIT) excl Other Income

0.50

-0.40

225.00%

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

0.20

-0.60

133.33%

Operating Profit Margin (Excl OI)

44.70%

-101.00%

14.57%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 26.00% vs -13.79% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 133.33% vs -500.00% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

23.00

22.50

2.22%

Operating Profit (PBDIT) excl Other Income

2.10

Interest

0.00

0.20

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

1.10

0.90

22.22%

Operating Profit Margin (Excl OI)

58.80%

64.10%

-0.53%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 2.22% vs 9.76% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 22.22% vs 200.00% in Dec 2023

All Annual Results

Company CV

About Genomed SA

Genomed SA

Pharmaceuticals & Biotechnology

Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

Company Coordinates

Company Details

Ul. Ponczowa 12 , WARSZAWA None : 02-971

Tel: 48 22 6446019

http://www.genomed.pl

Registrar Details